(NASDAQ: EXAS) Exact Sciences's forecast annual revenue growth rate of 11.61% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.13%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.32%.
Exact Sciences's revenue in 2025 is $2,828,128,000.On average, 7 Wall Street analysts forecast EXAS's revenue for 2025 to be $584,844,695,862, with the lowest EXAS revenue forecast at $583,569,505,193, and the highest EXAS revenue forecast at $587,108,347,938. On average, 7 Wall Street analysts forecast EXAS's revenue for 2026 to be $661,699,833,871, with the lowest EXAS revenue forecast at $646,178,348,862, and the highest EXAS revenue forecast at $678,774,938,756.
In 2027, EXAS is forecast to generate $749,166,972,813 in revenue, with the lowest revenue forecast at $734,630,553,731 and the highest revenue forecast at $778,142,096,661.